- Home
- CAPR vs OBT Comparison
CAPR vs OBT Comparison
Compare CAPR & OBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- OBT
- Stock Information
- Founded
- CAPR 2005
- OBT 1892
- Country
- CAPR United States
- OBT United States
- Employees
- CAPR N/A
- OBT N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- OBT Major Banks
- Sector
- CAPR Health Care
- OBT Finance
- Exchange
- CAPR Nasdaq
- OBT Nasdaq
- Market Cap
- CAPR 324.6M
- OBT 368.1M
- IPO Year
- CAPR N/A
- OBT N/A
- Fundamental
- Price
- CAPR $4.66
- OBT $26.96
- Analyst Decision
- CAPR Strong Buy
- OBT Buy
- Analyst Count
- CAPR 6
- OBT 1
- Target Price
- CAPR $23.17
- OBT $29.00
- AVG Volume (30 Days)
- CAPR 1.9M
- OBT 21.8K
- Earning Date
- CAPR 11-10-2025
- OBT 10-29-2025
- Dividend Yield
- CAPR N/A
- OBT 1.95%
- EPS Growth
- CAPR N/A
- OBT 18.38
- EPS
- CAPR N/A
- OBT 3.03
- Revenue
- CAPR $11,130,509.00
- OBT $115,418,000.00
- Revenue This Year
- CAPR N/A
- OBT $19.86
- Revenue Next Year
- CAPR $7,894.07
- OBT $7.20
- P/E Ratio
- CAPR N/A
- OBT $8.81
- Revenue Growth
- CAPR N/A
- OBT 17.75
- 52 Week Low
- CAPR $4.40
- OBT $20.97
- 52 Week High
- CAPR $20.75
- OBT $32.14
- Technical
- Relative Strength Index (RSI)
- CAPR 31.84
- OBT 61.41
- Support Level
- CAPR $5.52
- OBT $25.01
- Resistance Level
- CAPR $6.01
- OBT $27.00
- Average True Range (ATR)
- CAPR 0.49
- OBT 0.72
- MACD
- CAPR -0.06
- OBT 0.08
- Stochastic Oscillator
- CAPR 12.42
- OBT 78.39
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About OBT Orange County Bancorp Inc.
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.